Cargando…

IMPACT OF OBESITY SEVERITY AND DURATION ON PANCREATIC β-AND α-CELLS DYNAMICS IN NORMOGLYCEMIC NON-HUMAN PRIMATES

OBJECTIVE: Obesity is associated to high insulin and glucagon plasma levels. Enhanced β–cell function and β–cell expansion are responsible for insulin hypersecretion. It is unknown whether hyperglucagonemia is due to α-cell hypersecretion or to an increase in α-cell mass. In this study, we investiga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guardado-Mendoza, Rodolfo, Jimenez-Ceja, Lilia, Majluf-Cruz, Abraham, Kamath, Subhash, Fiorentino, Teresa Vanessa, Casiraghi, Francesca, Velazquez, Alberto Omar Chavez, DeFronzo, Ralph Anthony, Dick, Edward, Davalli, Alberto, Folli, Franco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906680/ https://www.ncbi.nlm.nih.gov/pubmed/23229736 http://dx.doi.org/10.1038/ijo.2012.205

Ejemplares similares

Coordinated Defects in Hepatic Long Chain Fatty Acid Metabolism and Triglyceride Accumulation Contribute to Insulin Resistance in Non-Human Primates
por: Kamath, Subhash, et al.
Publicado: (2011)

Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons
por: Chavez, Alberto O, et al.
Publicado: (2009)

The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
por: Guardado-Mendoza, Rodolfo, et al.
Publicado: (2013)

Energy Expenditure Evaluation in Humans and Non-Human Primates by SenseWear Armband. Validation of Energy Expenditure Evaluation by SenseWear Armband by Direct Comparison with Indirect Calorimetry
por: Casiraghi, Francesca, et al.
Publicado: (2013)

Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance
por: Chavez, Alberto O., et al.
Publicado: (2009)

The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans
por: Palavicini, Juan P., et al.
Publicado: (2021)

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
por: DeFronzo, Ralph A.
Publicado: (2009)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type
por: Miyazaki, Yoshinori, et al.
Publicado: (2009)

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!
por: Schwartz, Stanley, et al.
Publicado: (2013)

A novel experimental model for human mixed acinar–ductal pancreatic cancer
por: Doiron, Bruno, et al.
Publicado: (2018)

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Altered Insulin Clearance after Gastric Bypass and Sleeve Gastrectomy in the Fasting and Prandial Conditions
por: Salehi, Marzieh, et al.
Publicado: (2022)

Normoglycemic Diabetic Nephropathy: The Role of Insulin Resistance
por: Filippone, Edward J., et al.
Publicado: (2014)

Pathogenesis of Insulin Resistance in Skeletal Muscle
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2010)

Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Beta Cell Formation in vivo Through Cellular Networking, Integration and Processing (CNIP) in Wild Type Adult Mice
por: Doiron, Bruno, et al.
Publicado: (2016)

Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. Diabetes Care 2020;43:2296–2302
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Genetic Disruption of SOD1 Gene Causes Glucose Intolerance and Impairs β-Cell Function
por: Muscogiuri, Giovanna, et al.
Publicado: (2013)

In Vivo Actions of Peroxisome Proliferator–Activated Receptors: Glycemic control, insulin sensitivity, and insulin secretion
por: Eldor, Roy, et al.
Publicado: (2013)

Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
por: DeFronzo, R. A.
Publicado: (2010)

Indicators of metabolic syndrome in normotensive normoglycemic asthmatic patients
por: Sourg, Hanadi Abdelgadir Ahmed, et al.
Publicado: (2020)

Subclinical hypothyroidism increases insulin resistance in normoglycemic people
por: Yang, Wanyu, et al.
Publicado: (2023)

Mortality Rate Associated with Admission Hyperglycemia in Traumatic Femoral Fracture Patients Is Greater Than Non-Diabetic Normoglycemic Patients but Not Diabetic Normoglycemic Patients
por: Rau, Cheng-Shyuan, et al.
Publicado: (2017)

Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?
por: Liu, Jiwen (Jim), et al.
Publicado: (2012)

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2013)

PSUN299 GLP-1 Contribution to Insulin Secretory Response to Protein Ingestion and Insulin Kinetics Following Gastric Bypass and Sleeve Gastrectomy
por: Rayas, Maria, et al.
Publicado: (2022)

Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle
por: Alvarez-Canales, Mildred Fátima de la Luz, et al.
Publicado: (2021)

Postprandial Normoglycemic Hypokalemia—an Overlooked Complication to Gastric Bypass Surgery?
por: Abrahamsson, Niclas
Publicado: (2021)

OR26-07 Mild Physiologic Hyperglycemia Does Not Affect Glucose Mediated but Impairs Insulin-Mediated Suppression of Plasma Glucagon in Healthy Normal Glucose Tolerant Subjects
por: Tripathy, Devjit, et al.
Publicado: (2020)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
por: DeFronzo, Ralph A., et al.
Publicado: (2008)

201 Effects of GLP-1 on Glucose and Islet-Cell Secretory Responses to Protein Ingestion After Gastric Bypass or Sleeve Gastrectomy
por: Rayas, Maria S., et al.
Publicado: (2022)

Comparison of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in normoglycemic and hyperglycemic subjects
por: Mendes, Brena Barros, et al.
Publicado: (2018)

Metformin Alters Locomotor and Cognitive Function and Brain Metabolism in Normoglycemic Mice
por: Li, Wenjun, et al.
Publicado: (2019)

Sex-dependent effects of canagliflozin and dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice
por: Marcińczyk, Natalia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7h6db6sf3lhv5f0mgu788u4go7